Companies › Oncotelic
1 active drug program in 3 registered trials: 1 Phase 2, 1 Phase 3, 1 Phase 1; Oncology, Ophthalmology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Trabedersen (OT-101) Transforming growth factor beta-2 mRNA antisense inhibitor | TGFB2 | Phase 2 | Pancreatic Ductal Adenocarcinoma; Myopia, Progressive; Non-small Cell Lung Cancer | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04770610 | Trabedersen (OT-101) | Phase 3 | Myopia, Progressive | Ophthalmology | Mar 2027 |
| NCT06079346 | Trabedersen (OT-101) | Phase 2 | Pancreatic Ductal Adenocarcinoma | Oncology | Jun 2027 |
| NCT06579196 | Trabedersen (OT-101) | Phase 1 | Non-small Cell Lung Cancer | Oncology | Mar 2028 |
Cash of $0m on 2026-06-30; operating cash outflow about $1m a year; runway about 2 months at that burn, to Sep 2026; 0 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Dogwood Therapeutics Atossa Therapeutics Curis Processa Pharmaceuticals Moleculin Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.